Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 75.48

+1.4%

Nov 14 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2076)	1/4/2008 10:27:27 AM
From: Jibacoa	Read Replies (2) of 3722

HGSI is trading above the 11.50 level, up around 5.4% bigcharts.marketwatch.com It announced today that it will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, Jan 9 in Frisco. HGSI had an "upgrade" this week & some favorable comments about its drug development programs for hepatitis C and lupus & its artherosclerosis drug candidate Darapladib, which have the potential to generate royalties. Besides Darapladib, its diabetes drug candidate Syncria seems to be the next most promising product, with future royalties for sales estimated by some at 10% & with about $183M in milestone payments. It is also expected that HGSI will announce its first sales of ABthrax. for treatment of anthrax in late 2008. I will keep a modest "target" for HGSI around $15.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next